2021 CSCO Highlights: JW Therapeutics, Innovent, Ambrx, HUTCHMED Release Latest Data on Cancer Drugs
The 2021 Chinese Society of Clinical Oncology (CSCO) concluded on September 29th (Beijing Time). The event invited global biotechs and pharmaceutical companies to announce their latest oncology research and discovery, especially on tumor diagnosis and treatment.
In the 4-day forum, China’s JW Therapeutics and Innovent Biologics, WuXi AppTec-backed firm Ambrx Biopharma, and Hong Kong’s HUTCHMED presented the latest clinical data on their cancer drugs.
JW Therapeutics: CAR-T Therapy to Treat Patients with large B-cell Lymphoma
JW Therapeutics released the 1-year follow-up data of the Phase 2 trial of Carteyva (relmacabtagene autoleucel injection).
Carteyva is an anti-CD19 CAR-T therapy that was approved by China’s NMPA (National Medical Products Administration) to treat patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) drug. It is the sixth approved CAR-T therapy in the world and the first independently developed CAR-T therapy in China.
The Phase 2 data showed an increase in patients’ responses. The overall response rate was 77.6%. The complete response rate was 51.7%, while the 1-year overall survival (OS) was 76.8%, with a median follow-up of 17.9 months. The drug was generally well-tolerated in the trial.
|Related Article: Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?|
Innovent: A Bispecific Antibody to Treat Advanced Solid Tumor
Innovent announced the preliminary data on the Phase Ia trial of IBI315. The drug is a first-in-class anti-Her2/PD-1 bispecific antibody that was co-developed by Innovent and the U.S.-based Hanmi Pharmaceutical.
In Phase Ia, IBI315 showed a positive safety profile and an objective response rate (ORR) of 20% in patients with advanced Her2-expressing solid tumors. Senior Vice President of Innovent Dr. Hui Zhou said, “We are excited to see that IBI315 was well-tolerated with a manageable safety profile. The efficacy signal was also encouraging”.
Innovent will advance the drug to Phase Ib trial in the near future, where they can examine the efficacy of IBI315 to target Her2 positive and low-expressed tumors as a monotherapy and combination therapy with chemotherapy.
Ambrx Biopharma: ARX788 on HER2+ Gastric Cancer Patients
NovoCodex Pharmaceuticals is the Chinese partner of the U.S.-based Ambrx Biopharma (Ambrx). The firm announced the positive interim data of its metastatic gastric/gastroesophageal junction (GEJ) cancer drug, ARX788.
The drug showed an ORR of 44.4%, a median overall survival (mOS) of 10.7 months, and a tolerable safety profile. Meanwhile, Ambrx is preparing a Phase 2/3 trial for the drug.
HUTCHMED: Combine Surufatinib or Fruquintinib with PD-1 inhibitor
HUTCHMED revealed data on various Phase 2 trials. The Hong Kong firm combined surufatinib (SULANDA) or fruquintinib (ELUNATE) with a PD-1 inhibitor and explored the efficacy and safety data as a combination therapy.
A Phase 2 trial investigated the combination of surufatinib with toripalimab on patients with advanced neuroendocrine carcinoma. The result showed a median overall survival of 10.3 months, a disease control rate (DCR) of 71.4%, and a median progression-free survival (PFS) of 4.14 months.
Another Phase 2 trial combined fruquintinib with sintilimab to treat patients with advanced endometrial cancer. 4 of them were treatment-naïve, and 25 were pretreated. The data demonstrated an ORR of 100% in the treatment-naïve group and a median PFS that did not reach the standard. In the pretreated patients, data showed a DCR of 92%, a median PFS of 6.9 months, and an ORR of 32%.©www.geneonline.com All rights reserved. Collaborate with us: firstname.lastname@example.org